The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.
 
Ilse Anna Catharina Spiekman
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst); Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/Merck (Inst); Bristol Myers Squibb Foundation (Inst); Janssen-Cilag (Inst)
 
Laurien Joanna Zeverijn
No Relationships to Disclose
 
Birgit Geurts
No Relationships to Disclose
 
Karlijn Verkerk
No Relationships to Disclose
 
Soemeya Fooziye Haj Mohammad
No Relationships to Disclose
 
Vincent van der Noort
No Relationships to Disclose
 
Paul Roepman
No Relationships to Disclose
 
Wendy W.J. de Leng
No Relationships to Disclose
 
Anne M.L. Jansen
No Relationships to Disclose
 
Addy C.M. van de Luijtgaarden
No Relationships to Disclose
 
Theo Van Voorthuizen
No Relationships to Disclose
 
Tineke E. Buffart
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - AmMax Bio (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Emile E. Voest
Leadership - Mosaic Therapeutics; Sanofi
Stock and Other Ownership Interests - Mosaic Therapeutics; Sanofi
Consulting or Advisory Role - Biogeneration Ventures; InteRNA
Research Funding - astrazeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
 
Henk M.W. Verheul
No Relationships to Disclose